Absci Corporation

Overview

Absci is a clinical-stage biopharmaceutical company that applies an AI-native approach to creating antibody therapeutics. Its Integrated Drug Creation platform pairs a de novo antibody design engine with rapid wet-lab validation in a lab-in-the-loop feedback cycle: Data to Train → AI to Create → Wet Lab Validate. The company focuses on underexplored biological mechanisms with high unmet need and aims to deliver first-in-class or best-in-class antibodies more capital-efficiently than traditional discovery.

Platform and capabilities

• Origin-1: a de novo antibody design engine built to target challenging epitopes, including “zero-prior” epitopes.
• AbsciGen and AbsciBind: components of Origin-1 used for generation and filtering/evaluation of antibody candidates.
• Lab-in-a-loop: fast wet-lab validation that converts AI-generated designs into validated candidates.
• Facilities and assays: a combined 77,000+ sq ft wet-lab and dry-lab facility capable of high-throughput measurements (for example, SPR affinity) and other assays; uses the bacterial SoluPro platform and the ACE assay for developability and functional assessment, and also uses public datasets.
• Capabilities enable target discovery, AI-guided antibody design (including multispecifics), AI-guided lead optimization across multiple parameters (binding, developability, manufacturability), and in silico epitope evaluation.
• Origin-1 (released January 2026) is reported to produce atomically accurate designs against multiple targets, with some designs confirmed by Cryo-EM structures.

Pipeline and programs (as of December 31, 2025)

• ABS-201 (anti-prolactin receptor, PRLR)
  • Indications: androgenetic alopecia (AGA) and endometriosis.
  • Status: HEADLINE Phase 1/2a trial started December 2025 (NCT07317544); the first three single-ascending-dose cohorts have been dosed with favorable safety to date.
  • Upcoming milestones: interim safety/tolerability and PK data in H1 2026; interim proof-of-concept data in H2 2026; full PoC data in early 2027.
  • Endometriosis plan: Phase 2 planned for Q4 2026, subject to HEADLINE results and regulatory considerations; POC data expected in 2027.
• ABS-101
  • Target: TL1A pathway for inflammatory bowel disease (IBD).
  • Status: Phase 1 in healthy volunteers initiated May 2025. Absci has prioritized ABS-201 for near-term value and plans to seek a partner for ABS-101.
• Preclinical programs
  • Ongoing discovery and preclinical efforts include ABS-301 (oncology), ABS-501 (HER2) and others.
• Partnerships and collaboration programs
  • Absci has collaboration agreements with companies including Merck, AstraZeneca and Almirall and has generated revenue from drug-creation activities under partnered programs.

Financial and operating highlights (as of and for the year ended December 31, 2025)

• Cash and liquidity: $144.3 million in cash, cash equivalents and marketable securities.
• Revenue: 2025 revenue derived from drug-creation activities for partnered programs.
• Net loss: $115.2 million in 2025; $103.1 million in 2024.
• Accumulated deficit: $624.8 million.
• Headcount: 140 employees.
• Headquarters and offices: principal offices in Vancouver, Washington; international offices in Zug, Switzerland and Belgrade, Serbia.
• Capital and financing: company has used equity offerings and debt to fund operations, maintains a shelf registration (Form S-3), operates a post-IPO equity program, and established an ATM program in August 2025 with TD Securities (USA) LLC for up to $100 million.

Intellectual property

• Patent portfolio: 69 issued/granted patents and 53 pending patent applications worldwide, including 12 issued U.S. patents and 20 pending U.S. applications.
• Coverage: patents covering the Integrated Drug Creation platform and related technologies, with estimated expirations generally between 2033 and 2045 (subject to adjustments and extensions).
• Trademarks: Absci’s stylized A logo, Absci®, SoluPro®, Bionic SoluPro®, Unlimit with us®, and other marks.

Market, competition and operational considerations

• Market position: competes in AI-driven biologics discovery and antibody design, alongside traditional biologics discovery groups and other computational drug-design firms. The platform is intended to shorten discovery timelines and reduce discovery costs.
• Operational risks: dependence on external contract manufacturers and CROs for certain activities, potential supply chain and manufacturing risks, and considerations related to international operations and cross-border data.

Summary assessment

Absci combines computational design with rapid laboratory validation to create antibody candidates. The company is advancing internal programs—most prominently ABS-201—while also generating revenue through drug-creation collaborations with pharmaceutical partners. Financially, Absci is in a pre-commercial, investment-heavy phase with a cash position of about $144 million, ongoing operating losses, and continued investment in platform development, clinical programs and platform expansion. The team is modest in size and headquartered in Vancouver, WA, with additional international sites.